Alex Tang
Articles
- General
- Theology
- Paul
- Karl Barth
- Spiritual Formation
- Christian Education
- Spiritual Direction
- Spirituality
- Worship
- Church
- Parenting
- Medical
- Bioethics
- Books Reviews
- Videos
- Audios
- PhD dissertation
Spiritual writing
- e-Reflections
- Devotions
- The Abba Ah Beng Chronicles
- Bible Lands
- Conversations with my granddaughter
- Conversations with my grandson
- Poems
- Prayers
Nurturing/ Teaching Courses
- Sermons
- Beginning Christian Life Studies
- The Apostles' Creed
- Child Health and Nutrition
- Biomedical Ethics
- Spiritual Direction
- Spiritual Formation
- Spiritual formation communities
- Retreats
Engaging Culture
- Bioethics
- Glocalisation
- Books and Reading
- A Writing Life
- Star Trek
- Science Fiction
- Comics
- Movies
- Gaming
- Photography
- The End is Near
My Notebook
My blogs
- Spiritual Formation on the Run
- Random Musings from a Doctor's Chair
- Random Sermons from a Doctor's Chair
- Random Writings from a Doctor's Chair
- Random Spirituality from a Doctor's Chair
Books Recommendation
---------------------
Medical Students /Paediatric notes
Dengue Vaccine: To Vaccinate or not to Vaccinate, that is the question.
Dr Alex Tang
Dengvaxia (Sanofi Pasteur) is a live attenuated tetravalent chimeric vaccine
made using recombinant DNA technology by adding the four serotypes of dengue
virus into a yellow fever vaccine strain. There are ongoing phase III trials in
Latin America and Asia involving over 31,000 children between the ages of 2 and
14 years. In the first reports from the trials, vaccine efficacy was 56.5% in
the Asian study and 64.7% in the Latin American study in patients who received
at least one injection of the vaccine. Efficacy varied by serotype. These are
the preliminary only as the trails are still ongoing.
In both trials, vaccine reduced by about 80% the number of severe dengue cases.
A closer look at the data shows that in Latin American and Asia at the 3rd year
of follow-up showed that the efficacy of the vaccine was 65.6% in preventing
hospitalization in children older than 9 years of age on the third year of
followup. The response was greater in children who has been infected by dengue
fever before (81.9%). The vaccine was approved in Mexico, Philippines, and
Brazil in December 2015. Dengvaxia consists of three injections at 0, 6 and 12
months.
Other dengue vaccines may take a few more years to be available. Notable are
DENVax (Inviragen/Takeda), TetraVax-DV (National Institute of Allergy and
Infectious Diseases), TDENV PIV (GlaxoSmithKline) and V180 (Merck). DENVax looks
promising as it combines dengue serotype 1,3 and 4 unto virus type 2 making it a
purely dengue vaccine. It is being developed at Mahidol University in Bangkok.
Currently all these are only in the phase 1 and 2 stages of development and it
may be many years before it can be used.
There is a current dengue epidemic in many Asian countries with the number of
cases and death increasing every month. Measures to control the vector, the
Aedes mosquito, whether by reducing its breeding grounds, destroying the larvae,
and killing of adults by fogging has not been proven effective in stamping the
epidemic. Due to the ineffective measures, there is a loud public outcry and
pressure on the respective governments to fast track the approval of Dengvaxia
as what has happened in India where in January 2016, barely a month after the
vaccine was approved for use in Mexico, Philippines and Brazil, the Indian
government decided to waive a planned large scale trial and approve the use of
the vaccine in the subcontinent. This means that India will not have any data on
phase 3 and 4 clinical data conducted on her own people. The approval was based
on phase 3 clinical data done in other countries. There always a risk when a new
vaccine is introduced without adequate local data in a local population.
The WHO Strategic Advisory Group of Experts (SAGE) on Immunization is currently
reviewing the evidence for Dengvarix and key considerations include vaccine
safety, vaccine efficacy, disease burden, programmatic suitability, and
cost-effectiveness. It is expected that it will submit its findings in April
2016. There is one major paper that describe the various trials done for
Dengvaxia. It was published in New England Journal of Medicine on 24 September
2015. It collects data from various trials during a 25 month period (two years
+one month). For a vaccine study, there is insufficient numbers and time for its
true efficacy to be determined. There is also not much data to show whether
people who received the vaccine may develop a more severe form of dengue when
further infected. This could be the fastest record for a clinical paper to be
published and the vaccine approved for use in Mexico, Brazil and Philippines.
Other countries, for example Thailand (in which the 4 of the extension trials
has been done) have not approved the use of the vaccine.
There is a dilemma here. On one hand, there is a full brown epidemic in
progress. But this epidemic has been ongoing for many years so it may be call an
endemic. On the other hand, there is a vaccine that is available though its true
effectiveness is not really known. Furthermore, the safety profile, long term
side effects and other side effects of this vaccine is also not known. There is
not enough data available. Should we pressurize the Ministry of Health to
approve this vaccine and allow its widespread use? The event of the Influenza
H1N1 pandemic comes to mind. Because of the public outcry and panic, most
governments stockpiled millions of dollars’ worth of Tamiflu, an antiviral
agent. Tamiflu is not effective against H1N1. This is a known fact at the
beginning of the pandemic. Yet that did not prevent governments from wasting
their scarce resources from stocking up the antiviral agent.
In view of this dilemma, I will suggest two things. First, the Ministry of
Health in cooperation with Sanofi to conduct a few large scale clinical trials
of the efficacy and effectiveness of Dengvarix on Malaysians in Malaysia. This
should give us the clinical data we need to make informed decisions about the
vaccine. Second, we (the Malaysian public and healthcare professionals) should
be patient and wait for the WHO recommendations that should be out in April this
year. A point of note is that Brazil’s approval of the vaccine in December last
year is conditional also to the WHO recommendation, which means it is not freely
available in Brazil yet.
To conclude, when a fellow professional, who knew of my caution about using
Dengvarix asked, “What will you tell your patient who is sick with dengue that
you did not offered to give the vaccine?” My reply is that, “What will you tell
your patient whom you had given the vaccine and come down with more severe form
of dengue?”
19 January 2016
